Abstract
Miller Fisher syndrome (MFS) is characterized by ataxia, areflexia, and ophthalmoparesis. Here we present a case of MFS mimicking Wernicke encephalopathy (WE) during pregnancy. A 31-year-old woman at 8 weeks of gestation presented with diplopia and ataxia after experi-encing nausea and vomiting for several weeks. We initiated thiamine based on a suspicion of WE, which produced no clear effects. However, her symptoms began to improve following intravenous immunoglobulin treatment, and other findings finally lead to a diagnosis of MFS. Because ataxia and ophthalmoparesis can be misdiagnosed as WE during pregnancy, clini-cians should consider MFS in the differential diagnosis.
References
1. Wakerley BR, Uncini A, Yuki N. GBS Classification Group. Guil-lain-Barré and Miller Fisher syndromes–new diagnostic classification. Nat Rev Neurol. 2014; 10:537–544.
2. Alvis JS, Hicks RJ. Pregnancy-induced acute neurologic emergen-cies and neurologic conditions encountered in pregnancy. Semin Ultrasound CT MR. 2012; 33:46–54.
3. Sharma SR, Sharma N, Masaraf H, Singh SA. Guillain-Barré syndrome complicating pregnancy and correlation with maternal and fetal outcome in North Eastern India: a retrospective study. Ann Indian Acad Neurol. 2015; 18:215–218.
4. Ono M, Sato H, Shirahashi M, Tomioka N, Maeda J, Watanabe K, et al. Clinical features of miller-fisher syndrome in pregnancy. Case Rep Obstet Gynecol. 2015; 2015:840680.
5. Kim YH, Lee SJ, Rah SH, Lee JH. Wernicke's encephalopathy in hy-peremesis gravidarum. Can J Ophthalmol. 2002; 37:37–38.
6. Kim JK, Bae JS, Kim DS, Kusunoki S, Kim JE, Kim JS, et al. Prevalence of anti-ganglioside antibodies and their clinical correlates with Guillain-Barré syndrome in Korea: a nationwide multicenter study. J Clin Neurol. 2014; 10:94–100.
7. Chan LY, Tsui MH, Leung TN. Guillain-Barré syndrome in pregnancy. Acta Obstet Gynecol Scand. 2004; 83:319–325.
8. Arányi Z, Kovács T, Sipos I, Bereczki D. Miller Fisher syndrome: brief overview and update with a focus on electrophysiological findings. Eur J Neurol. 2012; 19:15–20. ,e1-e3.
9. Elovaara I, Apostolski S, van Doorn P, Gilhus NE, Hietaharju A, Honkaniemi J, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol. 2008; 15:893–908.